Genetic Alterations and Resectability Predict Outcome in Patients with Neuroblastoma Assigned to High-Risk Solely by MYCN Amplification.

Frank BertholdAngela ErnstSandra AckermannChristoph BartenhagenHolger ChristiansenBarbara HeroCarolina RosswogDietrich von SchweinitzThomas KlingebielIrene SchmidThorsten SimonMatthias Fischer

Published in: Cancers (2021)

Neuroblastoma patients attributed to high risk solely by MYCN amplification have generally a more favorable outcome. Mutations of genes of the RAS and/or p53 pathways and incomplete resection are the main risk factors predicting poor outcome.

Keyphrases

risk factors
end stage renal disease
genome wide
ejection fraction
newly diagnosed
chronic kidney disease
nucleic acid
prognostic factors
peritoneal dialysis
copy number
bioinformatics analysis
genome wide identification